Our previous study showed that the features of epidermal growth factor receptor (EGFR)-RAS signaling in penile squamous cell carcinoma (SCC) suggested potential benefits of anti-EGFR monoclonal antibodies (mAbs) for penile SCC.
Here, we report, for the first time, a combination of nimotuzumab (an EGFR mAb) with chemotherapy that resulted in a partial response in a 44-year-old patient with penile SCC, who developed bilateral inguinal node metastasis after primary partial penile amputation. The literature of case reports of anti-EGFR mAbs in penile SCC was also reviewed.
Written by:
Men HT, Gou HF, Qiu M, He JP, Cheng K, Chen Y, Ge J, Liu JY. Are you the author?
Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Reference: Anticancer Drugs. 2014 Jan;25(1):123-5.
doi: 10.1097/CAD.0000000000000024
PubMed Abstract
PMID: 24263192
UroToday.com Penile and Urethral Cancers Section
